

101526029

PTO1 Rec'd PCT/PTC 28 FEB 2005
PATENT

S/N Unknown


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	YOUSSEF	Examiner:	Unknown
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	Herewith	Docket No.:	11757.80USWO
Title:	<u>METHODS FOR DETECTING BREAST AND OVARIAN CANCER</u>		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 495842415 US
Date of Deposit: February 28, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By: 
Name: David Ortiz

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in an International Search Report mailed March 1, 2004.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

10/526029

BT01 Rec'd PCT/PT 28 FEB 2005

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612)332.5300

By: 
Douglas P. Mueller
Reg. No. 30,300

Dated: February 28, 2005

DPM/pjk

23552

PATENT TRADEMARK OFFICE

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11757.80USWO	Application Number: 10/1526029 Unknown
			Applicant: YOUSEF	
			Filing Date: Herewith	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	02/37112	May, 2002	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Kim, et al., "Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer", British Journal of Cancer (2001) 85(5), 643-650				
		Dong, et al., "Differential Splicing of KLK5 and KLK7 in Epithelial Ovarian Cancer Produces Novel Variants with Potential as Cancer Biomarkers", Clinical Cancer Research, vol. 9, 1710-1720, May, 2003				
		Yousef, et al., "Down-Regulation of the Human Kallikrein Gene 5 (KLK5) in Prostate Cancer Tissues", The Prostate 51:126-132, May, 2002				
		Yousef, et al., "The New Kallikrein-like Gene, KLK-L2. Molecular Characterization, Mapping, Tissue Expression, and Hormonal Regulation", The Journal of Biological Chemistry, vol. 274, no. 53, Issue of December 31, pp. 37511-37516, 1999				

23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	